

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: MAILLIET et al.

Examiner: JARRELL, Noble E.

Application No.: 10/658,394

Art Unit: 1609

Filed: September 10, 2003

Title: Chemical Derivatives and Their Application as Antitelomerase Agents

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs

last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

February 27, 2007
Date


Kelly L. Bender, Reg. No. 52,610
Attorney/Agent for Applicant

Sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8995
Telefax (908) 231-2626

Sanofi-Aventis Docket No. ST99049G1 US DIV

Under the Paperwork Reduction Act of 1995, no persons are required to res

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/658,394
Filing Date	09-26-2003
First Named Inventor	MAILLIET
Group Art Unit	1809
Examiner Name	JARRELL, Noble E.
Attorney Docket Number	ST99049G1 - US - DIV

U.S. PATENT DOCUMENTS[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date	
Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter

code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial

possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on

the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.